Contact Us

Yes. CTR2 rescue experiments require attention to intracellular targeting: • Construct design: use a codon-modified SLC31A2 sequence with a small C-terminal tag (FLAG, HA). CTR2 has 3 transmembrane domains and intracellular trafficking determinants. • Endosomal/lysosomal localization validation: confirm intracellular localization by LAMP1 or Rab9 co-staining — CTR2 functions primarily at endosomes/lysosomes. • Transport-deficient rescue: methionine-rich motif mutations enable structure-function studies of copper coordination. • Functional readout: rescue should restore intracellular copper handling and platinum chemotherapy sensitivity profiles. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC29A2 (ENT2)'s role as an equilibrative nucleoside transporter or its contributions to nucleoside analog drug uptake. The Knockout line is the standard tool for asking whether ENT2 is required for nucleoside transport — ENT2 is broadly expressed and transports both purine and pyrimidine nucleosides as well as nucleobases. Overexpression is useful for testing nucleoside analog drug uptake or for distinguishing ENT2-specific functions from ENT1 (SLC29A1). For ENT2 research, the EDITGENE Knockout in HCT 116 is particularly relevant for studying nucleoside analog chemotherapy uptake (cytarabine/Ara-C, gemcitabine, fludarabine, cladribine) in a cancer cell context. ENT1 paralog expression analysis is important given functional overlap. ENT inhibitors (dipyridamole, NBMPR) specificity testing benefits from this knockout. Rescue with wild-type or transport-deficient ENT2 enables structure-function studies.

Yes. ENT2 rescue experiments are well-established for nucleoside transporter research: • Construct design: use a codon-modified SLC29A2 sequence with a small C-terminal tag (FLAG, HA). ENT2 has 11 transmembrane domains in the canonical ENT family architecture. • Transport-deficient rescue: substrate-binding pocket mutations enable structure-function studies. • Drug sensitivity rescue: nucleoside analog (cytarabine, gemcitabine) sensitivity restoration in ENT2-null cells confirms rescue functionality. • Functional readout: rescue should restore nucleoside uptake (³H-thymidine, ³H-uridine) and nucleoside analog drug sensitivity. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC36A1 (PAT1)'s role as a proton-coupled amino acid transporter or its specific contributions to intestinal absorption of small amino acids and amino acid-like drugs. The Knockout line is the standard tool for asking whether PAT1 is required for proton-dependent uptake of glycine, proline, alanine, and γ-aminobutyric acid (GABA) — particularly relevant in HCT 116, which has intestinal epithelial origins. Overexpression is useful for testing transport activity in heterologous systems and for assessing drug-substrate interactions. For PAT1 research, the EDITGENE Knockout in HCT 116 is highly informative for intestinal amino acid absorption and oral drug bioavailability studies — PAT1 contributes to apical uptake of certain GABA-related drugs (vigabatrin, gabapentin analogs) and δ-aminolevulinic acid (5-ALA used in photodynamic therapy). Rescue with wild-type or transport-deficient PAT1 enables structure-function studies, and is a critical specificity control for PAT1-mediated drug uptake research.

Yes. PAT1 rescue experiments require attention to proton-coupling and pH-dependence: • Construct design: use a codon-modified SLC36A1 sequence with a small C-terminal tag (FLAG, HA). PAT1 has 11 transmembrane domains — N-terminal tags must not disrupt topology. • Transport-deficient rescue: conserved residue mutations in proton-binding sites or substrate-binding pockets enable structure-function studies. • pH-dependence: PAT1 transport is highly pH-sensitive — rescue assays should be performed under controlled extracellular pH conditions (typically pH 5.5-6.5 for optimal activity). • Functional readout: rescue should restore proton-coupled amino acid uptake measured by ³H-glycine or related substrate uptake. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation for intestinal-relevant transport studies.

The choice depends on whether you are studying SLC5A6 (SMVT)'s role in intestinal biotin and pantothenate uptake or its emerging functions in colorectal cancer drug delivery research. The Knockout line is the standard tool for asking whether SMVT is required for intestinal vitamin transport in an epithelial cancer context. Overexpression is useful for transport activity studies and for biotin-conjugate drug delivery research. For intestinal SMVT research, the EDITGENE Knockout in HCT 116 is particularly relevant — HCT 116 supports intestinal-relevant transport studies, and SMVT overexpression has been explored as a biotin-targeted drug delivery strategy in colorectal cancer. This product complements the parallel SLC5A6 Knockout in HEK293 (also available); HCT 116 is preferred for intestinal absorption biology and CRC drug development contexts. Rescue with wild-type or transport-deficient SMVT is the standard specificity control.

Yes. SMVT rescue experiments in HCT 116 are particularly relevant for intestinal absorption research: • Construct design: use a codon-modified SLC5A6 sequence with a small C-terminal tag (FLAG, HA). Membrane topology must be preserved. • Polarized epithelial considerations: HCT 116 retains some epithelial polarity features — rescue can examine apical SMVT localization in epithelial-context cells. • Drug delivery readouts: rescue with wild-type SMVT enables direct comparison of biotin-conjugate drug uptake versus native biotin transport. • Functional readout: rescue should restore intestinal-relevant vitamin uptake activities. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation for intestinal-relevant SMVT studies.

The choice depends on whether you are studying SLC33A1 (AT-1)'s role as the principal ER acetyl-CoA transporter or modeling hereditary spastic paraplegia type 42 and congenital cataracts. The Knockout line is the standard tool for asking whether AT-1 is required for delivering acetyl-CoA to the ER lumen for protein acetylation — AT-1 is the only known ER acetyl-CoA importer, essential for substrate supply to ER acetyltransferases like ATase1/ATase2. Overexpression is useful for studying disease-associated AT-1 mutations or for biochemical reconstitution. For ER acetylation research, the EDITGENE SLC33A1 Knockout in HCT 116 is highly informative — AT-1 loss disrupts ER protein quality control, ER stress responses, and reticulophagy. SLC33A1 mutations cause SPG42 (autosomal dominant) and CATIFA syndrome (autosomal recessive) — disease variant rescue enables genotype-function correlation studies. Rescue with wild-type or transport-deficient AT-1 is the standard specificity control.

Yes. AT-1 rescue experiments require attention to ER membrane targeting: • Construct design: use a codon-modified SLC33A1 sequence with a small C-terminal tag (FLAG, HA). AT-1 has 11 transmembrane domains with ER targeting determinants. • ER localization validation: confirm ER localization by calnexin or PDI co-staining before functional assays. • Disease mutation rescue: SPG42-associated dominant mutations and CATIFA syndrome-associated recessive mutations enable comprehensive disease genotype-function studies. • Functional readout: rescue should restore ER acetyl-CoA transport (in vitro microsomal assays) and ER protein acetylation status (mass spectrometry). HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC52A3 (RFVT3)'s role in riboflavin (vitamin B2) transport or modeling Brown-Vialetto-Van Laere syndrome. The Knockout line is the standard tool for asking whether RFVT3 is required for cellular riboflavin uptake — RFVT3 is the principal apical riboflavin transporter in intestine. Overexpression is useful for transport kinetics studies and for testing therapeutic riboflavin supplementation strategies. For riboflavin biology research, the EDITGENE SLC52A3 Knockout in HCT 116 is particularly relevant for intestinal riboflavin absorption studies — HCT 116 has an intestinal epithelial origin. SLC52A3 mutations cause Brown-Vialetto-Van Laere syndrome type 2 (motor neuron disease responsive to riboflavin supplementation) — disease variant rescue enables genotype-function studies. Rescue with wild-type or transport-deficient RFVT3 is the standard specificity control.

Yes. RFVT3 rescue experiments are well-established for riboflavin biology research: • Construct design: use a codon-modified SLC52A3 sequence with a small C-terminal tag (FLAG, HA). The 11 transmembrane SLC52 architecture must be preserved. • BVVL mutation rescue: introduction of patient-derived SLC52A3 mutations enables disease genotype-function correlation in a controlled background. • Therapeutic riboflavin testing: rescue with disease variants combined with high-dose riboflavin treatment models the clinical therapeutic response. • Functional readout: rescue should restore ³H-riboflavin uptake activity. HCT 116 transduces efficiently with lentivirus and is appropriate for intestinal riboflavin absorption studies.

The choice depends on whether you are studying SLC4A11 (NaBC1)'s role in sodium-borate cotransport, ammonia transport, or its emerging functions in mitochondrial uncoupling and corneal endothelial dystrophy. The Knockout line is the standard tool for asking whether SLC4A11 is required for these activities — SLC4A11 is genetically linked to congenital hereditary endothelial dystrophy 2 (CHED2), Harboyan syndrome, and Fuchs endothelial corneal dystrophy. Overexpression is useful for studying disease-associated SLC4A11 mutations or for testing transport activity in heterologous systems. For SLC4A11 research, the EDITGENE Knockout in HCT 116 enables mechanistic studies of NH₃/H⁺ transport and emerging mitochondrial functions, though corneal endothelial physiology requires corneal endothelial cell models. Rescue with wild-type, transport-deficient, or CHED2-associated mutant SLC4A11 is the standard approach for genotype-function correlation studies and mechanistic dissection.

Yes. SLC4A11 rescue experiments require attention to membrane targeting and CHED2 disease biology: • Construct design: use a codon-modified SLC4A11 sequence with a small C-terminal tag (FLAG, HA). SLC4A11 has 14 transmembrane domains in the SLC4 family architecture — N-terminal tags must not disrupt membrane topology. • Disease mutation rescue: CHED2-associated mutations (e.g., R109H, G583R) and Harboyan syndrome variants enable comprehensive disease genotype-function correlation. • Surface localization validation: many CHED2 mutations cause ER retention rather than transport defects — surface biotinylation distinguishes trafficking from transport defects. • Functional readout: rescue should restore NH₃/H⁺ transport activity measured by intracellular pH dynamics. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC61A1 (MFSD5/hsMOT2)'s role as a molybdate transporter or its emerging functions in cellular molybdenum homeostasis. Note that SLC61A1 is the current HGNC-approved symbol; this gene is also widely referred to as MFSD5 or hsMOT2 in published literature, and is characterized as a high-affinity intracellular molybdate transporter, the human homolog of the algal MoT2 transporter. The Knockout line is appropriate for asking whether SLC61A1 is required for cellular molybdate uptake and downstream molybdopterin-dependent enzyme activities — particularly relevant given that molybdenum is an essential cofactor for sulfite oxidase, aldehyde oxidase, and xanthine dehydrogenase. Overexpression is useful for testing transport activity in heterologous systems or for studying substrate specificity. For molybdenum biology research, the EDITGENE SLC61A1 Knockout in HCT 116 enables study of molybdate-dependent enzymatic activities and the cellular consequences of disrupted molybdenum cofactor (Moco) biosynthesis in a colorectal cancer background. Rescue with wild-type or transport-deficient SLC61A1 is the standard specificity control for distinguishing transport activity from non-transport functions.

Yes. SLC61A1 rescue experiments require attention to membrane topology and transport mechanism: • Construct design: use a codon-modified SLC61A1 sequence with a small C-terminal tag (FLAG, HA). SLC61A1 is a 450-amino-acid MFS-family transporter with 12 predicted transmembrane domains — N-terminal tags must not disrupt membrane topology. • Transport-deficient rescue: substrate-binding pocket mutations or conserved MFS family residue mutations enable distinguishing transport activity from non-transport functions; the algal MoT2 homolog provides a reference for structure-function-relevant residue identification. • Surface and intracellular localization validation: SLC61A1 has been reported with both plasma membrane and intracellular membrane localization — confirm exogenous protein localization by imaging or fractionation before functional assays. • Functional readout: rescue should restore cellular molybdate uptake (measured by ICP-MS) and downstream molybdoenzyme activities (e.g., sulfite oxidase activity). HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation; the colorectal cancer background may be relevant given emerging connections between micronutrient transport and cancer metabolism.